Literature DB >> 20616157

Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.

Brian S Decker1, Michael B Kays, Mary Chambers, Michael A Kraus, Sharon M Moe, Kevin M Sowinski.   

Abstract

BACKGROUND AND OBJECTIVES: Short daily hemodialysis (SDHD) is an alternative to thrice-weekly HD because of its putative physiologic benefits. The purpose of this study was to investigate the effect of SDHD on the pharmacokinetics and pharmacodynamics of vancomycin. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Six noninfected adults who had anuria and were treated with SDHD were studied and received four dialysis sessions over 4 days. After completion of the first SDHD, each patient received vancomycin 15 mg/kg by intravenous infusion. Blood samples were collected over the ensuing 3 days during each subsequent inter- and intradialytic period. Pharmacokinetic parameters were determined. Serum concentration-time profiles were simulated for four vancomycin regimens with maintenance doses administered after every other SDHD. Area under the serum-concentration time curve (AUC) from 0 to 48 hours, 48 to 96 hours, and 96 to 144 hours were calculated, and Monte Carlo simulations were performed to determine the probability of target attainment at an AUC/minimum inhibitory concentration (MIC) ratio ≥800 for each 48-hour AUC at MICs ranging from 0.5 to 2.0 μg/ml.
RESULTS: Median (range) systemic clearance was 7.2 ml/min (5.3 to 10.0 ml/min), and dialytic clearance was 104 ml/min (94 to 106 ml/min). The steady-state volume of distribution was 55.4 L (34.8 to 77.2 L). At MICs ≤1 μg/ml, probability of target attainment was >90% for each 48-hour AUC when vancomycin was administered as a 20-mg/kg loading dose followed by 10 mg/kg after every other SDHD.
CONCLUSIONS: Vancomycin pharmacokinetic parameters in SDHD are consistent with data from thrice-weekly HD. A loading dose of 20 mg/kg followed by 10 mg/kg after every other SDHD provides adequate exposure for pathogens with MICs ≤1 μg/ml.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616157      PMCID: PMC3001762          DOI: 10.2215/CJN.03450410

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  37 in total

Review 1.  Daily hemodialysis: an update.

Authors:  Andreas Pierratos
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-03       Impact factor: 2.894

2.  High-efficiency short daily haemodialysis--morbidity and mortality rate in a long-term study.

Authors:  Manuel Carlos Martins Castro; Cláudio Luders; Rosilene Motta Elias; Hugo Abensur; João Egidio Romão Junior
Journal:  Nephrol Dial Transplant       Date:  2006-04-21       Impact factor: 5.992

Review 3.  Antimicrobial-resistant, Gram-positive bacteria among patients undergoing chronic hemodialysis.

Authors:  Erika M C D'Agata
Journal:  Clin Infect Dis       Date:  2002-10-28       Impact factor: 9.079

4.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Short daily versus conventional hemodialysis quality of life: a cross-sectional multicentric study in Spain.

Authors:  J Puñal Rioboó; E Sánchez-Iriso; A Ruano-Ravina; M L Varela Lema; D Sánchez-Guisande; L González-Rodríguez; J A Herrero; G Barril; F Maduell; J Hernández; A Otero; M A Bajo; R Sánchez
Journal:  Blood Purif       Date:  2009-07-08       Impact factor: 2.614

6.  Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study.

Authors:  Juan Carlos Ayus; M Reza Mizani; Steven G Achinger; Ravi Thadhani; Alan S Go; Shuko Lee
Journal:  J Am Soc Nephrol       Date:  2005-07-20       Impact factor: 10.121

7.  Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Pamela A Moise; George Sakoulas; Alan Forrest; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

8.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  CAHP-210 dialyzer influence on intra-dialytic vancomycin removal.

Authors:  Aroonrut Lucksiri; Meri K Scott; Bruce A Mueller; Richard J Hamburger; Kevin M Sowinski
Journal:  Nephrol Dial Transplant       Date:  2002-09       Impact factor: 5.992

View more
  5 in total

1.  Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis.

Authors:  Brian S Decker; Ahmed N Mohamed; Mary Chambers; Michael A Kraus; Sharon M Moe; Kevin M Sowinski
Journal:  Am J Nephrol       Date:  2012-07-18       Impact factor: 3.754

2.  Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach.

Authors:  Qingxia Liu; Huiping Huang; Baohua Xu; Dandan Li; Maobai Liu; Imam H Shaik; Xuemei Wu
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

Review 3.  Review of vancomycin-induced renal toxicity: an update.

Authors:  Oluwatoyin Bamgbola
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-30       Impact factor: 3.565

Review 4.  The Nephrotoxicity of Vancomycin.

Authors:  E J Filippone; W K Kraft; J L Farber
Journal:  Clin Pharmacol Ther       Date:  2017-06-05       Impact factor: 6.875

5.  Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration.

Authors:  Erin Chung; James A Tjon; Rosaleen M Nemec; Nadya Nalli; Elizabeth A Harvey; Christoph Licht; Winnie Seto
Journal:  Kidney Int Rep       Date:  2021-02-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.